<DOC>
	<DOCNO>NCT00912548</DOCNO>
	<brief_summary>The purpose study compare 5-year disease free survival rate ( DFS rate ) hormone receptor positive breast cancer patient add Goserelin Tamoxifen ovarian function suppression neo-/adjuvant cytotoxic chemotherapy hormone receptor positive breast cancer patient treat Tamoxifen .</brief_summary>
	<brief_title>Evaluating Role Addition Ovarian Function Suppression ( OFS ) Tamoxifen Young Women</brief_title>
	<detailed_description>- To compare overall Survival ( OS ) patient add Goserelin ( ZOLADEXTM ) Tamoxifen patient treat Tamoxifen alone premenopausal status - To compare 5-year disease free survival rate ( DFS rate ) patient take tamoxifen postmenopause patient add Goserelin ( ZOLADEXTM ) Tamoxifen induce ovarian function suppression premenopause - To determine tolerability safety Tamoxifen without concomitant Zoladex</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . Patients must undergo excision primary breast mass , proven histologically invasive breast adenocarcinoma . 2 . Patients must within 3 month last cycle chemotherapy . 3 . Patients must history normal menstruation prior start chemotherapy . 4 . Stage I , II III 5 . Woman , less equal 45 year age 6 . Hormone receptor status : ER+ve and/or PgR+ve 7. WHO performance status 0 , 1 2 . 8 . Patients treat cytotoxic chemotherapy pre post surgery . 9 . Adequate haematological function define haemoglobin 10g/dL , neutrophil count 1.5x109/L platelet 100x109/L . 10 . Adequate hepatic function define AST ALT 2.5xupper limit normal . Alkaline phosphatase 5xupper limit normal , unless bone metastasis absence liver disease . Renal function adequate define creatinine &lt; 175mmol/L . 1 . Patients whose primary breast cancer classify : ER ( ) , ER unknown 2 . Patients history hysterectomy oophorectomy 3 . Sarcomas squamous cell carcinoma breast eligible . 4 . Patients malignancy ( breast cancer ) within last 5 year , except adequately treat situ carcinoma cervix basal cell / squamous cell carcinoma skin . 5 . Investigational drug give within previous 4 week . 6 . Patients know unlicensed noncancer investigational agent . 7 . Patients thrombocytopaenia ( platelet &lt; 100 x 109/l anti coagulant therapy ( contraindicate due risk bleed i.m . injection Zoladex ) . 8 . Patients treat CMF ( cyclophosphamide/methotrexate/5fluorouracil ) prior chemotherapy 9 . Patients pregnant lactate ineligible .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>premenopause</keyword>
	<keyword>ovarian function suppression</keyword>
	<keyword>tamoxifen</keyword>
</DOC>